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SUMMARY 
Pancreatic islet inflammation contributes to the progression of  cell insulin secretion failure during 
obesity and type 2 diabetes. However, little is known about the nature and function of resident 
immune cells in this context and in homeostasis. Here we show that interleukin(IL)-33 is expressed 
by islet mesenchymal cells and enhanced by a diabetes milieu (high glucose levels, IL-1 and 
saturated fatty acid). IL-33 promotes  cell function through islet-resident group 2 innate lymphoid 
cells (ILC2) that elicit retinoic acid (RA)-producing capacities in macrophages and dendritic cells 
via the production of IL-13 and colony-stimulating factor 2. In turn, local RA signals to the  cells 
to increase insulin secretion. This islet IL-33/ILC2 axis is activated following acute β cell stress but 
is defective during chronic obesity. Accordingly, injections of IL-33 rescue islet function in obese 
mice. Our findings provide evidence for a novel immunometabolic crosstalk between islet-derived 
IL-33, ILC2 and myeloid cells that contributes to the maintenance of insulin secretion. 
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INTRODUCTION 
Type 2 diabetes occurs when pancreatic islet insulin secretion fails to compensate for insulin 
resistance due to obesity and genetic predisposition. It is now recognized that the immune system 
plays an important role in these processes and more generally is a regulator of metabolism. 
Experimental and clinical data have established that white adipose tissue (WAT) is a site of 
inflammation with ongoing activation of type 1 immunity during obesity-associated metabolic 
dysfunction (Donath et al., 2013). Interestingly, recent studies suggest a role for resident type 2 
immune cells to regulate WAT function and to limit the development of obesity. Indeed, 
alternatively activated macrophages, regulatory T cells (Tregs), eosinophils and group 2 innate 
lymphoid cells (ILC2) reside in lean WAT and are altered during obesity (Odegaard and Chawla, 
2015). This immunological switch from type 2 to type 1 immunity during obesity is supported by 
the study of two commonly used mouse strains, C57BL/6 and BALB/c, with marked differences in 
their immune repertoires (Mills et al., 2000). The Th1-permissive C57BL/6 mice are prone to 
develop obesity and insulin resistance, while the Th2-permissive BALB/c mice are generally 
protected against metabolic complications (Montgomery et al., 2013). 
 
During obesity and type 2 diabetes, pancreatic islets also undergo local stress and inflammation, 
although the etiology and mechanisms differ from adipose tissue. Glucose, saturated fatty acids 
and bacterial products stimulate islet-derived cytokines such as IL-1 and chemokines that may 
recruit immune cells (Boni-Schnetzler et al., 2009; Boni-Schnetzler et al., 2008; Maedler et al., 
2002). Macrophages are major contributors to islet inflammatory processes (Calderon et al., 2015; 
Cucak et al., 2014; Eguchi et al., 2012; Ehses et al., 2007; Jourdan et al., 2013; Nackiewicz et al., 
2014; Richardson et al., 2009). Accordingly, anti-inflammatory drugs are in development for the 
treatment of type 2 diabetes (Donath, 2014). However, as in other tissues, islet components of the 
immune system may have a beneficial role. Indeed, in experimental  cell ablation, alternatively 
activated macrophages promote  cell proliferation and regeneration, suggesting regulatory 
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functions of local macrophages (Criscimanna et al., 2014; Nir et al., 2007; Riley et al., 2015; Xiao 
et al., 2014). It remains unknown whether non-macrophage immune cells also reside in the islets 
at steady state and contribute to the maintenance of  cell function.  
 
In this study, we sought to identify immune cells residing in pancreatic islets and to investigate 
their possible role in physiology and disease. By comparing C57BL/6 and BALB/c mice, we 
identified mesenchymal cell-derived IL-33 as a novel immunoregulatory feature of islets likely to 
promote  cell function. We show that ILC2 are the primary IL-33-responsive cells in islets, which 
elicit retinoic acid (RA) production by macrophages and dendritic cells via the production of IL-13 
and colony stimulating factor 2 (Csf2, also known as GM-CSF). In turn, myeloid cell-derived RA 
enhances  cell insulin secretion. This novel islet IL-33/ILC2/myeloid cell axis is activated following 
acute  cell injury but is altered during obesity.  
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RESULTS  
Islet Mesenchymal Cells Produce IL-33 
Metabolic comparison of mouse strains showed that intra-peritoneal glucose tolerance tests (GTT) 
disclosed a more rapid clearance of blood glucose in BALB/c mice compared to age-matched 
C57BL/6 mice (Figure 1A) with comparable body and adipose mass (Figure S1A). Circulating 
insulin levels during GTT were similar between the groups (Figure 1B), despite BALB/c mice being 
more insulin sensitive than C57BL/6 mice (Figure S1B) and similar expression of uncoupling 
protein 1 (UCP1) in their brown adipose tissue (Figure S1C). These observations point to a 
stronger insulin secretion in BALB/c mice compared to C57BL/6 mice. Indeed, the insulinogenic 
index (defined as the ratio of the insulin to glucose areas under the curve) during GTT was higher 
in BALB/c mice compared to C57BL/6 mice (Figure 1C). To confirm a better  cell function, we 
tested pancreatic islets ex-vivo. Glucose-stimulated insulin secretion (GSIS) was much stronger 
in BALB/c islets compared to C57BL/6 islets (Figure 1D), with comparable islet insulin content 
(Figure S1D). We hypothesized that this difference may be due to the BALB/c mouse immune 
background and measured gene expression of type 2 immune initiators in islets (McKenzie et al., 
2014). BALB/c islets showed increased expression of Il33 but not of Tslp (Thymic stromal 
lymphopoietin) and Il25 compared to C57BL/6 islets (Figure 1E).  
We next employed an Il33–LacZ gene trap reporter strain to visualize the activity of the 
endogenous Il33 promoter in the pancreas (Pichery et al., 2012). Galactosidase staining revealed 
constitutive activity of the Il33 promoter in islets and to a much lesser extent in the exocrine 
pancreas (located in some vascular beds) of Il33Gt/+ mice, with no signal in the pancreas of Il33+/+ 
wildtype (WT) mice (Figure 1F and S1E). To study the cellular origin of IL-33, we sort-purified islet 
CD45+ immune cells and the CD45-negative remaining cells. Il33 mRNA levels were increased in 
the CD45- cells compared to the immune compartment (Figure 1G). We next analyzed islets 
isolated from a green fluorescent protein (GFP) IL-33 reporter mice by flow cytometry (Kallert et 
al., 2017; Oboki et al., 2010). GFP expression was exclusively detected in cells that were CD45-
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FSClowSSClow and negative for the Epithelial cell adhesion molecule (Epcam), suggesting a 
nonepithelial phenotype and thus not related to an endocrine origin (Figure 1H and I). The IL-33-
GFP+ cells were further classified as positive for the mesodermal stem cell antigen-1 (Sca-1) 
(Figure 1J) and they preferentially expressed the mesenchymal marker Vim (vimentin) and not the 
smooth muscle cell marker Acta2 (α-SMA) compared to  cell-enriched and other GFP- subsets 
(Figure S1F). We confirmed that sort-purified islet Sca-1+ cells were the primary population 
expressing vimentin in islets compared to  cell-enriched and other Sca-1- cells (Figure 1K).  
To characterize IL-33 in islets, we stimulated islets with components of a type 2 (obesity-
associated) diabetes milieu. High concentrations of recombinant IL-1, glucose and the saturated 
fatty acid palmitate induced IL-33 mRNA and protein in C57BL/6 and BALB/c mouse islets relative 
to controls (Figure 1L and S1G), with BALB/c islets overall producing more IL-33 than C57BL/6 
islets. Of note, IL-33 protein was undetectable in islet cell lysate isolated from IL-33-deficient 
(Il33Gt/Gt) mice compared to WT controls (Figure S1H). Similar induction of IL-33 was observed in 
islets isolated from human donors, especially in response to IL-1 (Figure 1M and S1I). Taken 
together, our results prompted us to investigate a possible role for mesenchymal cell-derived IL-
33 as a new islet stress signal regulating endocrine function. 
 
Islet IL-33-Responsive Cells Are Resident Group 2 Innate Lymphoid Cells  
Supporting a local role for IL-33, we sought to identify resident IL-33-responsive cells within islets. 
In contrast to Il33, its receptor Interleukin-1 receptor-like 1 (Il1rl1, encoding T1/ST2) was more 
expressed in CD45+ cells than in the non-immune cell fraction (Figure 2A). Using flow cytometry, 
we quantitatively profiled islet-dwelling immune cells of BALB/c and C57BL/6 mice fed a chow diet 
(gating strategy in Figure S2A). Islets generally contain an average of 6 pan CD45+ immune cells 
per islet, with macrophages being the main immune subset (Figures 2B-C). Interestingly, BALB/c 
mouse islets showed increased frequency and cell number of specific branches of innate immunity 
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including ILC2, dendritic cells and NK cells compared to C57BL/6 mice (Figure 2B-C). Islets of 
both strains contained similar amounts of T and B cells and scarce neutrophils and eosinophils 
(Figure 2B-C). We identified ILC2 as the primary immune subset expressing IL-33-receptor 
T1/ST2 within islets (Figure 2D). Rare Tregs were detectable among islet T cells and did not 
express T1/ST2 (data not shown). Of note, T1/ST2 was also not detectable on the surface of 
mouse insulin+  cells (data not shown). Islet-resident ILC2 were lineage negative and expressed 
the cell surface markers CD90.2, T1/ST2 and KLRG1 and the transcription factor GATA binding 
protein 3 (GATA3) (Figures 2E and S2A). Islet-resident ILC2 were more frequent among total 
CD45+ cells (Figure S2B) and expressed higher levels of T1/ST2 (Figure 2F) than ILC2 isolated 
from the exocrine stroma of the same pancreas, supporting islet ILC2 specificity. 
Immunofluorescence analyses confirmed the presence of ILC2 located inside the islets (Figure 
2G) or in a peri-islet position (Figure S2C) in Rag2-/- mouse pancreas. Freshly isolated islets and 
sort-purified pancreatic ILC2 produced significant amounts of type 2 immune cytokines including 
IL-5, IL-13 and Csf2 in response to IL-33 and IL-2 ex vivo (Figure 2H). ILC3 are also known to 
produce Csf2 (Mortha et al., 2014). Compared to GATA3+ ILC2, frequencies of RAR-related 
Orphan Receptor (ROR)γt+ ILC3 were very low in isolated islets and whole pancreata of mice fed 
a chow diet (Figure 2E and S2D), supporting ILC2 as a major source of Csf2 in islets. We next 
observed that IL-33-deficient mice exhibited a 42 ± 8 % decrease in ILC2 number in islets 
compared to WT controls (Figure I). Thus, resident ILC2 are the primary cells that may respond to 
IL-33 in islets and endogenous IL-33 is required to maintain the islet ILC2 population.  
 
IL-33 Promotes Insulin Secretion  
To examine the effects of IL-33 signaling in islet-resident ILC2 in vivo, C57BL/6 mice fed a chow 
diet were administered a single (acute) or three doses (chronic) every other day of saline or mouse 
recombinant IL-33. IL-33 did not alter body weight and adipose mass (Figure 3A). Acute and 
chronic IL-33 treatment significantly decreased fasting blood glucose and markedly enhanced 
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glucose clearance during GTT relative to saline controls (Figure 3B). Interestingly, circulating 
insulin levels during GTT tended to be boosted following a single injection of IL-33 and reduced 
upon chronic IL-33 treatment (Figure 3C). Notably, the insulinogenic index was increased upon 
both acute and chronic IL-33 treatments compared to controls (Figure 3D), pointing to overall 
increased insulin secretion and progressively enhanced glucose disposal. Supporting this 
hypothesis, islets isolated from IL-33-treated mice dose-dependently showed enhanced GSIS 
compared to saline controls (Figure 3E). IL-33-treated mouse islets also had a better insulin 
secretion relative to controls in response to membrane-depolarizing concentrations of potassium 
chloride, known to trigger robust secretory response (Figure 3F). Islet insulin content following 
both GSIS and potassium chloride-induced insulin secretion assays was not different between the 
groups (Figure S3A and B). Supporting a role for IL-33 to potentiate  cell function and not mass, 
IL-33 treatment did not alter pancreatic  cell area (Figure G), islet size distribution and islet  cell 
frequency compared to saline groups (Figures S3C and D). Interestingly, when the three doses of 
0.5 µg were administered together in a single injection of 1.5 µg, IL-33 did not significantly improve 
glucose tolerance and GSIS compared to saline and the usual chronic IL-33-treated groups, 
arguing for time-dependent improvement of  cell function (Figures S3E and F). 
We next investigated whether IL-33 administration improved insulin sensitivity in the peripheral 
organs. IL-33 did not affect overall insulin sensitivity as demonstrated by both insulin tolerance 
test (Figure 3H) and hyperinsulinemic-euglycemic clamps (Figure 3I). Accordingly, glucose 
infusion rate (Figure 3I) and endogenous glucose production (Figure S3G) during clamps were 
not different between the groups. Tissue glucose uptake was up-regulated in inguinal (Ing)WAT 
but not in skeletal muscle, epididymal (Epi)WAT and brown adipose tissue (Figure 3J). IngWAT is 
the most prone to beiging of its white adipocytes, which may contribute to the clearance of blood 
glucose (Kajimura et al., 2015). Recently, studies have identified a crucial role for IL-33 to elicit 
WAT beiging and regulate thermogenesis (Brestoff et al., 2015; Lee et al., 2015; Odegaard et al., 
2016). Under our conditions, although chronic IL-33 treatment increased Ucp1 mRNA levels in 
 9 
EpiWAT (Figure S3H), no change in UCP1 protein was observed in IngWAT of IL-33-treated mice 
compared to saline groups (data not shown). Importantly, IL-33 treatment still achieved significant 
improvement in the glucose clearance during GTT in Ucp1-/- mice compared to controls (Figure 
3K), indicating that recruitment of beige fat is dispensable for the IL-33-induced metabolic effect. 
We also performed pancreas perfusions to study in situ GSIS independently of peripheral glucose 
consumption. In this experimental setting, chronically IL-33-treated mice tended to have increased 
insulin secretion compared to saline-treated group (Figure S3I), further supporting IL-33 as an 
insulin secretagogue.  
To investigate endogenous IL-33 role in metabolism, we characterized IL-33-deficient mice under 
normal conditions. We did not observe any marked difference in body and adipose tissue mass, 
glucose tolerance and insulin sensitivity in Il33Gt/Gt compared to Il33+/+ littermates when fed a chow 
diet (Figure S3J-L). However, islets isolated from Il33Gt/Gt chow diet mice displayed an impaired 
insulin secretion compared to WT littermate islets during ex vivo GSIS (Figure 3L), without change 
in insulin content (Figure S3M). Only when challenged with a high fat diet, Il33Gt/Gt mice exhibited 
obesity, glucose intolerance and insulin resistance compared to WT controls (Figure S3N and O). 
Thus, IL-33 may be a critical regulator of  cell function and mediates rapid glucose-lowering 
effects by stimulation of insulin secretion.  
 
IL-33-Activated ILC2 Promote Insulin Secretion   
IL-33 administration increased the number of CD45+ cells and more specifically of ILC2, dendritic 
cells and eosinophils in islets compared to controls (Figure 4A, S4A and B). While the number and 
frequency of macrophages were decreased, T and B cell, NK cell and neutrophil populations were 
not significantly affected (Figure 4A and S4A). We also observed higher mRNA expression of 
typical ILC2-secreted factors including Il5 (known to mediate eosinophil activation), Il13 and Csf2 
in islets isolated from IL-33-treated mice compared to controls (Figure 4B). Down-regulation or no 
change were observed for gene expression of other type 2 immune genes including Areg 
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(encoding amphiregulin), Il10 and Tgfb1 (encoded Transforming growth factor-β) and type 1 
cytokines including Il1beta, Ccl2 and Cxcl1, while Il4, Interferon gamma (Ifng) and Il22 were 
undetectable (Figure S4C).  
We next investigated whether IL-33-induced insulin secretion was due to the presence of ILC2. 
Three doses of saline or IL-33 were administered to BALB/c WT, Rag2-/- and ILC2-deficient Rag2-
/-γc-/- mice. We observed that IL-33 significantly improved glucose tolerance and ex vivo GSIS in 
WT and Rag2-/- mice but not in Rag2-/-γc-/- mice compared to saline (Figure 4C and D), with a slight 
increase in insulin content in WT and Rag2-/- mice (Figure S4D). We next treated Rag2-/- mice with 
an anti-CD90.2 antibody, which is known to deplete ILC2 (Monticelli et al., 2011). Anti-CD90.2-
treated mouse islets showed a 58  6% decrease in ILC2 number (Figure 4E) and tended to have 
impaired GSIS compared to Immunoglobulin G (IgG) controls (Figure 4F), without change in 
insulin content (Figure S4E). 
To further confirm that IL-33 promotes insulin production in an ILC2-dependent manner, Rag2-/-
γc-/- mice were treated with IL-33 in the presence or absence of adoptively transferred pancreatic 
ILC2. ILC2-reconstituted Rag2-/-γc-/- mice supported IL-33-induced ILC2 expansion in their 
pancreata relative to controls (Figure S4F), without alteration of body and fat mass (Figure S4G). 
Strikingly, ILC2 transfer was sufficient to rescue IL-33-induced improvement in glucose tolerance 
test (Figure 4G) and ex vivo GSIS (Figure 4H) in Rag2-/-γc-/- mice, with similar circulating insulin 
levels and islet insulin content (Figure S4H and I). 
We next investigated whether ILC2 could have direct effects on  cells to promote insulin 
production by culturing islets with conditioned media of sort-purified pancreatic ILC2. We found 
that ILC2-conditioned media significantly improved islet GSIS compared to unconditioned medium 
controls (Figure 4I), without affecting insulin content (Figure S4J). Collectively, our data indicate 
that IL-33-induced insulin secretion is not a direct effect of IL-33 on  cells but requires the unique 
presence of ILC2 and ILC2-secreted factors. 
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IL-33/ILC2 Axis Elicits Retinoic Acid-Producing Capacities In Islet Myeloid Cells  
Islet ILC2 produce cytokines that are known to shape tissue-specific myeloid cell functional identity 
(Lavin et al., 2015). Notably, IL-13 and Csf2 imprint RA-producing capacities in macrophages and 
dendritic cells (Mortha et al., 2014; Yokota et al., 2009). We sought to determine whether the IL-
33/ILC2 axis also promoted RA production in islet resident myeloid cells. Vitamin A is oxidized by 
alcohol dehydrogenases to yield retinal. Retinal is then irreversibly converted to RA by aldehyde 
dehydrogenases (ALDH), the major isoform of which is encoded by Aldh1a2. Interestingly, IL-33 
administration dose-dependently up-regulated Aldh1a2 gene expression in islets compared to 
saline controls (Figure 5A). We sort-purified islet macrophages and dendritic cells from saline- and 
IL-33-treated mice. Each subset mainly expressed its lineage characteristic gene Emr1 (encoding 
F4/80) and Flt3, respectively, ensuring their identity (Figure S5A). Both islet macrophages and 
dendritic cells showed up-regulation of Aldh1a2 mRNA in IL-33-treated mice compared to controls 
(Figure 5B). We next measured the relative ALDH activity in islet individual myeloid cells by flow 
cytometry using a fluorescent substrate for ALDH (Yokota et al., 2009). Islets treated with ALDH 
inhibitory diethylaminobenzaldehyde was used as a negative control. According to the 
morphological analysis of islet macrophages, we identified two distinct populations, R1 and R2 
(Figure S5B). IL-33 treatment markedly increased ALDH activity in islet R1 macrophages and 
dendritic cells compared to controls (Figure 5C and D). Although the frequency of granular R2 
macrophages was increased in IL-33-treated mice relative to controls (Figure S5C), R2 
macrophage ALDH activity was not inhibited by diethylaminobenzaldehyde, pointing to cell 
autofluorescence (Figure S5D). Enhanced ALDH activity in both R1 macrophages and dendritic 
cells was observed in islets isolated from Rag2-/- mice but not Rag2-/-γc-/- mice following IL-33 
treatment, suggesting that IL-33-induced myeloid RA production is ILC2-dependent (Figure 5E-
F). Interestingly, dendritic cells overall had higher ALDH activity compared to macrophages in both 
saline- and IL-33-treated mice.  
 12 
To identify the ILC2-secreted mediators responsible for increased ALDH activity in myeloid cells 
during IL-33 treatment, we tested the effect of IL-13 and Csf2. We found that these two molecules 
together up-regulated the gene expression of Aldh1a2 in sort-purified islet macrophages (Figure 
5G) and in bone marrow-derived dendritic cells (Figure 5H) in vitro. Of note, recombinant IL-33 
did not induce Aldh1a2 in myeloid cells in vitro (data not shown). Islets cultured in presence of 
ILC2-conditioned media showed increased Aldh1a2 gene expression compared to control 
medium, which was hampered in the presence of combined anti-IL-13 and anti-Csf2 neutralizing 
antibodies (Figure 5I). Besides, islets showed increased Aldh1a2 gene expression when 
stimulated with IL-33 and IL-2 in vitro compared to controls, suggesting that resident IL-33-
responsive ILC2 polarize neighboring myeloid cells (Figure 5J). Accordingly, IL-33-deficient mice 
displayed reduced ALDH activity in islet resident dendritic cells (Figure 5K) but not macrophages 
(Figure S5E) compared to WT littermates. Collectively, these data support that IL-33-activated 
ILC2 imprint islet resident myeloid cells with RA-producing capacities in an IL-13 and Csf2-
dependent ways. Interestingly, dendritic cells but not macrophages are dependent on endogenous 
IL-33 to sustain a physiological level of ALDH activity in islets.  
 
IL-33-Mediated Insulin Secretion Is Dependent On Vitamin A 
Our findings prompted us to investigate whether IL-33-induced insulin secretion is dependent on 
RA signaling. The pharmaceutical form of RA, all-trans RA, significantly induced insulin secretion 
in islets in vitro, with a similar insulin content (Figure 6A and S6A). Many RA biological activities 
are mediated by RA receptors (RARα, RAR, and RARγ) or retinoic X receptor (RXRα), whose 
gene expression can be self-induced (Wu et al., 1992). We observed that all-trans RA exclusively 
up-regulated the gene expression of Rarb (encoding RAR) in islets compared to controls (Figure 
6B). Accordingly, ILC2-conditioned media failed to increase insulin secretion in islets cultured in 
presence of the synthetic RAR receptor antagonist LE135 compared to control, with similar islet 
insulin content during GSIS (Figure 6C and S6B).  
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We next conducted a vitamin A deprivation study. To avoid any developmental confounding 
effects, the diet was started at 6 weeks of age for 10 weeks. Vitamin A deprivation did not induce 
alterations in body weight nor in insulin sensitivity compared to the control chow diet (Figure S6C 
and D). Both vitamin A deficient diet- and chow diet-fed mice were chronically treated with three 
doses of IL-33 or saline. Notably, vitamin A deficiency did not hinder IL-33-mediated activation of 
ILC2 with similar ILC2 and eosinophil numbers in islets isolated from control and vitamin A 
deficient mice (Figure 6D). In contrast, IL-33 administration failed to induce Aldh1a2 gene 
expression in islets isolated from vitamin A-deprived mice compared to the corresponding chow 
diet and saline groups (Figure 6E). Reduced ALDH activity was confirmed in islet dendritic cells 
and to a lesser extent in R1 macrophages isolated from IL-33-treated vitamin A deprived versus 
chow diet mice (Figure S6E). We did not observe any difference in blood glucose and plasma 
insulin levels during GTT between the groups (Figure S6F). However, the insulinogenic index was 
significantly increased in IL-33-treated compared to saline-treated chow diet mice but not in 
vitamin A-deprived mice (Figure 6F), suggesting that IL-33-induced insulin secretion is reduced in 
the absence of vitamin A. To further investigate the contribution of vitamin A to IL-33-induced 
insulin effect, we performed ex vivo experiments with isolated islets. IL-33 treatment significantly 
increased insulin secretion during both GSIS and potassium chloride-induced insulin secretion in 
islets isolated from chow diet but not from vitamin A-deprived mice compared to saline groups 
(Figure 6G and H), without marked change in insulin content (Figure S6G and H). Therefore, 
enhancement of  cell function by IL-33 is dependent on dietary vitamin A and its conversion into 
RA.   
Chronic Versus Acute Islet Inflammation Regulates The IL-33/ILC2 Axis  
To investigate the role of the IL-33/ILC2 axis in a pathophysiological context, mice were fed a 
chow or high fat diet for 3 to 7 months. At 3 months, obese mice already showed increased body 
weight and impaired GTT (Figure S7A-B). Notably, obesity was associated with a pathological 
increase in plasma insulin levels to compensate for insulin resistance and characterized by the 
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absence of glucose-induced insulin production at 15 min compared to baseline (Figure S7C). Islets 
isolated from obese mice showed a progressive decrease in Il33 mRNA levels after 3 and 7 
months of high fat diet and in IL-33 protein after 3 months compared to controls (Figure 7A and 
B). Accordingly, islets isolated from obese mice displayed decreased frequency and number of 
ILC2 than those isolated from chow diet controls (Figure 7C). This was accompanied by a late 
decrease in islet Aldh1a2 gene expression in obese mice relative to controls (Figure 7D). 7 month-
obese mice treated with three doses of IL-33 showed a drastic improvement in glucose clearance 
during GTT (Figure 7E), despite no change in body and WAT weights (Figure S7D). IL-33-treated 
mice overall lowered their insulin levels but rescued GSIS at 15 min during GTT compared to 
baseline (Figure 7F). Of note, obesity did not hinder IL-33-mediated type 2 immunity with a 
significant accumulation of ILC2 and subsequently eosinophils in islets compared to saline 
controls (Figure S7E). 
We next employed a model of acute  cell injury following a single high-dose of streptozotocin, 
selectively toxic to  cells (Figure S7F). Streptozotocin treatment induced a strong diabetic 
phenotype characterized by increased fasting blood glucose, decreased fasting circulating insulin 
levels and body weight loss compared to buffer-treated mice (data not shown). Streptozotocin-
treated mice showed increased islet Il33 mRNA levels compared to controls (Figure 7G) and a 
more diffuse galactosidase staining in Il33Gt/+ mice (Figure S7G), pointing towards a more active 
Il33 promoter. Accordingly, streptozotocin treatment increased the frequency and number of ILC2 
in islets compared to controls (Figure 7H), together with increased islet Aldh1a2 gene expression 
(Figure 7I). IL-33 treatment in streptozotocin-induced diabetic mice significantly improved the 
fasting glycemia and prevented body weight loss compared to controls (Figure 7J), with a 
tendency towards increased fasting plasma insulin levels on day 9 (Figure S7H) and larger 
epiWAT (Figure S7I). In contrast, administration of the ILC2-depleting anti-CD90.2 antibody in 
streptozotocin-induced diabetic Rag2-/- mice tended to worsen fasting blood glucose levels 
compared to IgG controls (Figure 7K). We did not detect any difference in glycemia when Il33Gt/Gt 
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and WT littermates were treated with a similar streptozotocin high dose (data not shown). Taken 
together, our results show that the IL-33/ILC2 axis is defective in islets during obesity and is 
activated following acute β cell stress. ILC2 may not only boost insulin secretion but also contribute 
to  cell recovery following injury.   
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DISCUSSION  
Our work established a role for type 2 immunity in the regulation of pancreatic islet physiology 
orchestrated by IL-33. Many studies described IL-33 expression in mouse tissues at steady state, 
including in epithelial cells of barrier tissues, fibroblast-like cells in lymphoid organs or endothelial 
cells in adipose tissue (Liew et al., 2016). In patients suffering from chronic pancreatitis, IL-33 was 
mainly expressed by activated pancreatic stellate cells (Masamune et al., 2010). Here, using two 
different models of IL-33 reporter mice, we identified IL-33-producing cells as Sca-1+vimentin+ 
mesenchymal cells located inside pancreatic islets. In mouse and human islets, IL-33 gene 
expression and protein levels were increased upon stimulation with components of a diabetic 
milieu, proposing IL-33 as a novel stress signal in islets. Indeed, designated as an « alarmin », IL-
33 is usually released after cell injury to alert the immune system and initiate repair processes 
(Liew et al., 2016). We detected IL-33 protein only in islet cell lysate and not in the supernatant. 
This argues in favor of IL-33 nuclear localization and the requirement for cell death for its proper 
release. Alternatively, detection of IL-33 in islet cell supernatant may be hindered by its low 
concentration and rapid inactivation in the extracellular environment through caspase-mediated 
cleavage and oxidation of cysteine residues (Liew et al., 2016). Although the role of islet 
mesenchymal cells remains to be explored, we showed that IL-33 promotes and sustains  cell 
function in chow diet-fed mice. Indeed, administration of a single or three doses of IL-33 
significantly stimulated insulin secretion. In severely obese mice, IL-33 injections rescued GSIS 
during GTT relative to controls. Conversely, islets isolated from IL-33-deficient mice displayed 
impaired GSIS compared to WT littermates. Supporting our findings, mice lacking IL-33 receptor 
T1/ST2 develop hyperglycemia associated with impaired insulin secretion when fed a high fat diet 
(Miller et al., 2010).  In contrast to published data linking IL-33 deficiency to obesity, glucose 
intolerance (Brestoff et al., 2015) and thermogenesis defect (Odegaard et al., 2016), we did not 
detect any other metabolic alterations in chow diet-fed Il33Gt/Gt knockout mice relative to WT 
 17 
littermates. These divergent findings may arise from variations in dietary fat and sucrose content 
and the use in our study of littermate controls backcrossed on a pure genetic background. 
 
Growing emphasis was laid on the protective role of IL-33 in obesity. This effect has been widely 
attributed to IL-33-induced modulation of WAT inflammation towards type 2 immunity that may 
promote insulin sensitivity (Kolodin et al., 2015; Miller et al., 2010; Molofsky et al., 2013; Molofsky 
et al., 2015; Vasanthakumar et al., 2015). In genetically or diet-induced obese mice, IL-33 
treatment led to an improvement in glucose homeostasis compared to controls. However, this 
phenotype was not associated with enhanced insulin sensitivity (Miller et al., 2010; 
Vasanthakumar et al., 2015). Here, we also showed that IL-33 treatment improves glucose 
tolerance in chow diet mice independently of insulin sensitivity. Recently, IL-33 was shown to elicit 
WAT beiging and to regulate the splicing of Ucp1 mRNA (Brestoff et al., 2015; Lee et al., 2015; 
Odegaard et al., 2016). It is now recognized that beige adipose cells have the capacity to consume 
glucose to produce heat (Kajimura et al., 2015).  While glucose uptake was increased in ingWAT 
of IL-33-treated mice, chronic IL-33 treatment failed to induce UCP1 protein in WAT compared to 
controls, suggesting that our experimental settings are not yet sufficient to stimulate the growth of 
functional beige fat. Indeed, publications reporting IL-33-mediated beiging were based on daily IL-
33 injections for more than a week (Brestoff et al., 2015; Lee et al., 2015). Importantly, treatment 
of Ucp1-deficient mice confirmed that IL-33 metabolic effects do not rely on recruitment of beige 
adipocytes to clear the blood glucose. Thus, IL-33 treatment in chow diet-fed mice mainly lowers 
glycemia by rapid stimulation of insulin secretion in  cells, independently of changes in both 
insulin sensitivity and adipose beiging. The fact that IL-33 treatment tends to lower plasma insulin 
levels during GTT may be in response to alternative IL-33 glucose-lowering effects, including 
glucose consumption by increased number of activated immune cells compared to controls. 
 
IL-33 signals through the T1/ST2 receptor identified on the surface of many immune cells. 
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Although IL-33 was shown to induce oxidative stress in the MIN6 insulinoma  cell line (Hasnain 
et al., 2014), we did not detect T1/ST2 on the surface of mouse islet  cells but on resident immune 
cells. In contrast to autoimmune type 1 diabetic mouse models, there are only a limited number of 
studies addressing the nature of islet immune cells in WT mice at steady state or in the context of 
type 2 diabetes. Besides, the different protocols used to isolate islets and disperse them into single 
cells may affect immune cell purity, number and surface markers. Likewise, the amount of islets 
(from one or several pooled mice) used for immune profiling may greatly influence the outcomes 
considering that immune cells represent only a small fraction of islet cells, that we and others have 
estimated to range from 2 to 10 immune cells per islet (Calderon et al., 2015; Calderon et al., 
2008; Cucak et al., 2014; Ehses et al., 2007). In our study, we used clean handpicked islets that 
were isolated from pools of mice. We confirmed that macrophages are the major immune cell 
population existing within islets of chow diet mice (Calderon et al., 2015; Cucak et al., 2014). Yet 
we also noticed cells from the non-macrophage compartment including ILC2, dendritic cells and 
NK cells that were more abundant in BALB/c mice compared to C57BL/6 mice. Among them, we 
identified resident ILC2 as the primary islet IL-33-responsive cells, which were located inside and 
in the periphery of islets, likely to influence  cell function.  
 
ILC2 are rare yet potent tissue-resident cells under physiological conditions (Gasteiger et al., 
2015). Emerging studies have extended their biological functions to immunosurveillance, tissue 
protection, repair processes and now adipose beiging (Brestoff et al., 2015; Lee et al., 2015; 
McKenzie et al., 2014). Our work provides further evidence on how these cells regulate the host 
metabolism by identifying a novel ILC2 metabolic function in islets. IL-33 treatment in Rag2-/- mice, 
Rag2-/-γc-/- mice and ILC2-adoptively transferred Rag2-/-γc-/- mice confirmed that IL-33 does not 
act directly on  cells but is dependent on the presence of ILC2 and ILC2-secreted factors to 
promote insulin secretion. IL-33 administration led to a massive accumulation of ILC2 and 
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subsequently dendritic cells and eosinophils. Thus, we cannot rule out a possible role for 
eosinophils in IL-33-mediated metabolic benefits. The IL-33/ILC2 axis also contributes to  cell 
protection in the context of obesity- and streptozotocin-induced  cell stress, supporting its 
functional role. Similar to adipose tissue (Molofsky et al., 2013), obesity is associated with a loss 
of islet ILC2. This may partly be explained by the phenotypic plasticity that ILC2 exhibit in response 
to inflammatory cues including IL-1 (Ohne et al., 2016), known to be elevated during obesity and 
type 2 diabetes in islets (Donath et al., 2013). 
  
Islet ILC2 produced IL-13 and Csf2 that are recognized to induce RA-producing capacities in 
myeloid cells (Mortha et al., 2014; Yokota et al., 2009). Here, we show that approximately 30% of 
resident dendritic cells and 5% of macrophages displayed ALDH activity in islets under 
physiological conditions. These RA-producing capacities are markedly increased after IL-33 
treatment compared to saline groups but diminished (for dendritic cells) in IL-33-deficient mice 
compared to WT mice. We propose that ILC2-derived IL-13 and Csf2 may be the mediators 
promoting ALDH activity in islet myeloid cells. Recently, a similar crosstalk was described in the 
mouse intestine. Microbiota-driven IL-1 production by macrophages promotes the release of Csf2 
by RORγt+ILC3, which in turn regulates RA production in phagocytes and leads to local Treg 
homeostasis (Mortha et al., 2014). Our study reveals that mesenchymal cell-derived IL-33 initiates 
an immune crosstalk between islet ILC2 and neighboring myeloid cells to produce RA and promote 
insulin secretion, not related to classical immune responses.  
 
Previous studies have established that vitamin A and its metabolite RA play a crucial role in the 
maintenance of pancreatic endocrine functions. Vitamin A-deficient diet or RA-related gene 
deficiencies blocked the development of fetal pancreatic islets and abrogates the maintenance of 
 cell mass and function during adulthood (Brun et al., 2015; Chertow et al., 1987; Martin et al., 
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2005; Matthews et al., 2004; Perez et al., 2013; Trasino et al., 2016). However the cellular source 
of RA in islets in adult mice remained elusive. Our data identified islet resident macrophages and 
especially dendritic cells as endogenous RA producers. We used a vitamin A-deficient diet that 
was given to 6-week-old adult mice to avoid any developmental issues. In contradiction to 
published data (Trasino et al., 2016), vitamin A-deprived mice did not show impaired glucose 
homeostasis per se. However, we observed that IL-33 treatment did not promote  cell function in 
vitamin A-deprived mice in contrast to IL-33 treatment in control mice, supporting that IL-33-
induced insulin secretion requires vitamin A and its conversion to RA.  
  
In summary, our study identifies the first immunometabolic crosstalk within islets that is initiated 
by IL-33-releasing mesenchymal cells and leads to a novel insulin secretagogue effect. IL-33 acts 
on resident ILC2 that elicit RA-producing capacities in myeloid cells to support insulin secretion. 
This work represents an important step towards our understanding of islet resident immune cells 
and show that ILC2 can influence  cell physiology. In addition to blocking pro-inflammatory type 
1 immunity, selective activation of type 2 immunity via IL-33 or ILC2 stimulation may offer 
therapeutic avenues for novel immunotherapies in patients suffering from type 2 diabetes. Indeed, 
targeting the IL-33/ILC2 pathway in obesity appears optimal as it promotes both rapid insulin 
secretion and long-term adipose beiging development, without affecting insulin sensitivity and thus 
further risk of body weight gain.  
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FIGURE LEGENDS 
Figure 1 
IL-33 Expression In Pancreatic Islets  
(A and B) (A) Blood glucose and (B) plasma insulin levels during GTT in C57BL/6 and BALB/c 
mice. n = 25 mice each from 5 cohorts. 
(C) Insulinogenic index defined as the ratio of the insulin to glucose areas under the curve during 
GTT. n = 25 mice each from 5 cohorts. 
(D) Insulin release from islets isolated from C57BL/6 and BALB/c mice during GSIS. n = 13 each 
from 3 independent experiments. 
(E) Gene expression of Il33, Tslp and Il25 in islets isolated from C57BL/6 and BALB/c mice. n = 
10 each from 3 independent experiments. n.d. = not detectable. 
(F) Representative picture of Il33 promoter-driven β-galactosidase expression in pancreata of 
Il33+/+ wildtype (WT) and Il33+/Gt mice (n = 4). Black line indicates islet’s perimeter. 
(G) Il33 gene expression in sort-purified islet CD45+ immune cells and CD45- cell fraction isolated 
from pooled C57BL/6 females. n = 6 independent experiments. 
(H) Representative plots of GFP and Epcam expression by islet cells isolated from Il33gfp/wt and 
C57BL/6 mice. n=3.   
(I) Representative FSC/SSC profile of islet CD45+, GFP+ and GFP- cell fractions (n=3).   
(J) Histograms of Sca-1 expression by islet GFP- and GFP+ cells (n=2).   
(K) Representative vimentin staining (n=2) in sort-purified islet Sca-1-  cell-enriched cells (high 
FSC/SSC profile), other Sca-1- cells and Sca-1+ cells.  
(L and M) IL-33 protein concentrations in (L) C57BL/6 and BALB/c mouse and (M) human islet 
cell lysates treated with IL-1, glucose, bovine serum albumin (BSA) and/or BSA-Palmitate. n = 3 
independent experiments and n = 5 donors, respectively. 
Data are represented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; Statistical 
significance (p) was determined by one-way (L and M when normalized to baseline) or two-way 
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analysis of variance (ANOVA) (A, B, D and E) with Bonferroni’s post-hoc test and Student's t test 
(C and G). See also Figure S1. 
 
Figure 2 
Islet IL-33-Responding Cells Are Resident Group 2 Innate Lymphoid Cells 
(A) Il1rl1 gene expression in sort-purified islet CD45+ immune cells and CD45- cell fraction isolated 
from pooled C57BL/6 females. n = 6 independent experiments. 
(B and C) Immune cell profiling of islets isolated from pools of C57BL/6 and BALB/c mice. Cell 
abundance is expressed as (B) percentage of total CD45+ cells and (C) absolute cell number per 
1000 islets. n = 3-5 independent experiments each (see complete gating strategy in Figure S2A). 
(D) Mean fluorescence intensity (MFI) of T1/ST2 expressed on the surface of islet immune cells.  
n = 6-12 independent experiments.  
(E) Representative plot of GATA3+ILC2 and RORγt+ILC3 among CD45+Lin-CD90.2+ cells in 
BALB/c islets. n = 3 independent experiments. 
(F) Histograms of T1/ST2 expression by ILC2 isolated from islets and exocrine stroma of the same 
mouse pancreas. n = 4 independent experiments. 
(G) Representative picture (n = 4 mice) of C57BL/6 Rag2-/- mouse pancreas stained for CD45.2 
(blue), KLRG1 (red), NKp46 (green) and DAPI (white). Blue dashed line indicates islet’s perimeter. 
(H) Cytokine concentrations in culture supernatants of 90 BALB/c islets (n = 19 each from 6 
independent experiments) or 1000 sort-purified C57BL/6 pancreatic ILC2 (n = 12 each from 3 
independent experiments) in response to IL-33 and IL-2. 
(I) Representative plots and quantification of ILC2 in islets isolated from Il33+/+ and Il33Gt/Gt mice. 
n = 4 cohorts.  
Data are represented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; Statistical 
significance (p) was determined by one-way ANOVA (D) with Bonferroni’s post-hoc test and 
Student's t test (A-C and I when normalized to baseline). 
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Figure 3 
IL-33 Promotes Glucose Disposal And Insulin Secretion  
C57BL/6 mice were treated with saline or IL-33 (500 ng) injection for one or three doses every 
other day. 
(A-E) (A) Body weight (before and after treatment), inguinal white adipose tissue (IngWAT), 
epididymal (Epi)WAT and brown adipose tissue (BAT) mass, (B) fasting glycemia and blood 
glucose, (C) plasma insulin levels and (D) insulinogenic index during GTT in saline- and IL-33-
treated mice. n = 20, 19 and 15 (except for BAT n = 6-7), respectively, from 5 cohorts. p represents 
comparison to saline group. 
(E and F) Insulin release from islets isolated from saline- and IL-33-treated mice during (E) GSIS 
(n = 19 each from 4 independent experiments) and (F) potassium chloride (KCl)-induced insulin 
secretion assays (n = 12 each from 3 independent experiments). 
(G) Quantification of insulin+  cell area in pancreata of saline- and IL-33-treated mice. n = 9-10 
mice from 3 cohorts (one section per animal). 
(H) Blood glucose levels normalized to baseline during insulin tolerance test in saline- and IL-33-
treated mice. n = 8 mice each from 2 cohorts.  
(I and J) (I) Glucose infusion rate (GIR) and (J) tissue glucose uptake in skeletal (Sk.) muscle, 
IngWAT, EpiWAT and BAT during hyperinsulinemic-euglycemic clamps in saline- and IL-33-
treated mice. n = 5-6 each from 2 cohorts. 
(K) Blood glucose levels during GTT in saline- and IL-33-treated Ucp1-/- mice. n = 6-7 
representative of 2 cohorts.  
(L) Insulin release from islets isolated from Il33+/+ and Il33Gt/Gt littermate mice during GSIS. n = 11 
each from 3 cohorts. 
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Data are represented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; Statistical 
significance (p) was determined by one-way (B, D and J) or two-way (B, C, E, F, L and K) ANOVA 
with Bonferroni’s post-hoc test and Student's t test (K). See also Figure S3. 
 
Figure 4 
ILC2 Contribute To IL-33-Induced Insulin Secretion  
(A) Absolute immune cell number per 1000 islets isolated from pooled saline- and IL-33-treated 
(three doses) C57BL/6 mice. n = 3 to 12 independent experiments.  
(B) Gene expression of Il13, Il5 and Csf2 in islets isolated from saline- and IL-33-treated mice. n 
= 10-12 from 4 cohorts. 
(C) Blood glucose levels in BALB/c WT, Rag2-/- and Rag2-/-γc-/- mice treated with saline or three 
doses of IL-33 during GTT. n = 10-15 mice each from 3 cohorts. 
(D) Insulin release during GSIS from islets isolated from saline- and IL-33-treated BALB/c WT (n 
= 12-13 each), Rag2-/- mice (n = 20 each) and Rag2-/-γc-/- mice (n = 14-15 each) from 3-4 cohorts. 
(E) Representative plots and quantification of ILC2 in islets isolated from Immunoglobulin G (IgG)- 
or anti-CD90.2-treated BALB/c Rag2-/- mice. n = 3 cohorts.  
(F) Insulin release during GSIS from islets isolated from Rag2-/- treated with IgG or anti-CD90.2 
antibody. n = 16 each from 3 cohorts. 
(G and H) Sort-purified pancreatic ILC2 or PBS were transferred to IL-33-treated Rag2-/-γc-/- mice. 
(G) Blood glucose levels during GTT (n = 3 mice) and (H) insulin release during GSIS (n = 16 from 
4 mice) from 2 cohorts. 
(I) Insulin release during GSIS of C57BL/6 islets treated with ILC2-conditioned media or control 
medium. n = 19 per group from 4 independent experiments. 
Data are represented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; Statistical 
significance (p) was determined by one-way (B) or two-way (C, D, F, H and I) ANOVA with 
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Bonferroni’s post-hoc test and Student's t test (A and E when normalized to baseline). See also 
Figure S4.  
 
Figure 5 
IL-33 Regulates Retinoic Acid-Producing Capacities In Islet Myeloid Cells  
(A) Gene expression of Aldh1a2 in islets isolated from saline- and IL-33-treated mice (one and 
three doses of 500ng i.p.). n = 9-10 from 3 cohorts. 
(B) Gene expression of Aldh1a2 in sort-purified islet macrophages (MΦ) and dendritic cells (DC) 
isolated from saline- and IL-33-treated mice. n = 4 independent experiments. 
(C and D) Histograms and frequencies of (C) ALDH+ R1 MΦ and (D) ALDH+ DC in islets isolated 
from saline- and IL-33 (three doses)-C57BL/6 WT treated mice. n = 5 cohorts. Islets treated with 
the ALDH inhibitory diethylaminobenzaldehyde (DEAB) were used as a negative control. 
(E and F) Frequencies of (E) ALDH+ R1 MΦ and (F) ALDH+ DC in islets isolated from saline- and 
IL-33 (three doses)-treated BALB/c Rag2-/- and Rag2-/-γc-/- mice. n = 3 cohorts. 
(G and H) Gene expression of Aldh1a2 in (G) sort-purified islet macrophages (n = 4 independent 
experiments) or (H) bone marrow-derived DC (BM-DC; n = 10 from 3 independent experiments) 
stimulated with recombinant IL-13 and Csf2.  
(I) Gene expression of Aldh1a2 in C57BL/6 islets treated with ILC2-conditioned media (CM) or 
control medium with or without anti(α)-IL-13 and α-Csf2 neutralizing antibodies. n = 8-9 per group 
from 3 independent experiments. 
(J) Gene expression of Aldh1a2 in islets isolated from BALB/c mice and stimulated with IL-2 and 
IL-33 in vitro. n = 9 per group from 3 independent experiments. 
(K) Frequencies of ALDH+ DC in islets isolated from Il33+/+ and Il33Gt/Gt littermates. n = 3 cohorts. 
Data are represented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; Statistical 
significance (p) was determined by one-way ANOVA (A, C-H) and two-way ANOVA (I and K) with 
Bonferroni’s post-hoc test and Student's t test (B and J). See also Figure S5.  
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Figure 6  
IL-33-Induced Insulin Secretion Requires The Retinoic Acid-Precursor Vitamin A  
(A) Insulin release during GSIS from islets treated with DMSO or all-trans RA in vitro. n = 15-16 
each from 3 independent experiments. 
(B) Gene expression of retinoic acid receptors in islets treated with DMSO or all-trans RA. n = 6 
each from 2 independent experiments. 
(C) Insulin release during GSIS from islets treated with ILC2-conditioned media (CM) or control 
medium in the presence of the retinoic acid receptor (RAR)  antagonist LE135 or DMSO. n = 12-
13 each from 3 independent experiments. 
(D-H) C57BL/6 mice fed a control chow (CD) or vitamin A deficient (VAD) diet were given saline 
or IL-33 (three doses).  
(D) Frequencies and absolute number of ILC2 and eosinophils in islets isolated from IL-33-treated 
mice fed a CD or VAD. n = 3 from 3 cohorts. 
(E) Gene expression of Aldh1a2 in islets isolated from saline- and IL-33-treated mice fed a CD or 
VAD. n = 6-10 each from 4 cohorts. 
(F) Insulinogenic index during GTT in saline- and IL-33-treated mice fed a CD or VAD. n = 11-13 
mice each from 3 cohorts. 
(G-H) Insulin release during (G) GSIS and (H) potassium chloride-stimulated insulin secretion 
assays from islets isolated from saline- and IL-33-treated mice fed a CD or VAD.  n = 8-9 each 
from 2 cohorts.  
Data are represented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; Statistical 
significance (p) was determined by one-way ANOVA (E and F) and two-way ANOVA (A-C, G and 
H) with Bonferroni’s post-hoc test. See also Figure S6.  
 
Figure 7  
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The IL-33/ILC2 Axis Is Altered During Chronic Versus Acute Islet Stress  
(A) Gene expression of Il33 in islets isolated from mice fed a normal chow diet (CD) or a high fat 
diet (HFD) for 3 and 7 months. n = 12-17 each from 3 cohorts. 
(B) IL-33 protein concentrations in islet cell lysate of CD- or HFD-fed mice for 3 months. n = 6-8 
each from 2 cohorts. 
(C) Representative plots, frequencies and absolute number of ILC2 in islets isolated from mice 
fed a CD or a HFD for 3 months. Gated on CD45+Lin-CD90.2+ cells. n = 4 cohorts. 
(D) Gene expression of Aldh1a2 in islets isolated from mice fed a CD or a HFD for 3 and 7 months. 
n = 12-17 each from 3 cohorts. 
(E and F) (E) Blood glucose and (F) plasma insulin levels during GTT in mice fed a HFD for 7 
months and treated with saline or IL-33 (three doses). Ratio of insulin secretion between times 0 
and 15 min is shown. n = 10 mice each from 2 cohorts. 
(G) Gene expression of Il33 in islets isolated from buffer or streptozotocin (STZ)-treated mice on 
day 15 post-injection. n = 6-7 each from 2 cohorts. 
(H) Representative plot, frequencies and absolute number of ILC2 in islets isolated from buffer or 
STZ-treated mice on day 15 post-injection. Gated on CD45+Lin-CD90.2+ cells. n = 3 cohorts. 
(I) Gene expression of Aldh1a2 in islets isolated from buffer or STZ-treated CD mice on day 15 
post-injection. n = 6-7 each from 2 cohorts.  
(J) C57BL/6 mice were treated with STZ on day 0. From day 6, mice were administered saline or 
IL-33 (three doses) every other day. Fasting blood glucose levels and body weight were 
monitored. n = 12-13 mice from 3 cohorts. 
(K) C57BL/6 Rag2-/- mice were given STZ on day 0 and treated with IgG or anti(α)-CD90.2 
antibody on days 6 and 8. Fasting blood glucose levels were monitored and normalized to 
baseline. n = 9-10 mice from 3 cohorts.  
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Data are represented as the mean ± SEM. *p < 0.05, ***p < 0.001; Statistical significance (p) was 
determined by two-way ANOVA (A, D-F) with Bonferroni’s post-hoc test and Student's t test (B, 
C, F- J). See also Figure S7. 
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STAR★METHODS 
KEY RESOURCES TABLE 
 
CONTACT FOR REAGENT AND RESOURCE SHARING  
 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Elise Dalmas (elise.dalmas@unibas.ch).  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  
Mice  
Male (and where indicated, female) C57BL/6 and BALB/c wildtype mice were either purchased 
from Charles River and Janvier Labs, respectively, or were bred in-house. C57BL/6 Rag2-/- mice 
were from Taconic and bred in-house. BALB/c Rag2-/- mice were a gift from A. Rolink (University 
of Basel, Switzerland). BALB/c Rag2-/-γc-/- (C;129S4-Rag2tm1.1Flv Il2rgtm1.1Flv/J) were purchased 
from Jackson Laboratories. IL33Gt/Gt mice (Il33Gt(IST10946B6-Tigm)) were generated with insertion of a 
gene trap cassette containing the LacZ (bgeo) reporter into intron 1 of the Il33 locus as described 
previously (Pichery et al., 2012). Il33Gt/Gt mice were first backcrossed for 4 generations with 
C57BL/6J mice to obtain >98% purity using speed congenics. Il33Gt/Gt, Il33Gt/+ and Il33+/+ mice were 
all littermates. IL33 reporter mice (Il33gfp/wt) were derived from the Il33-/- mice (Il33tm1Snak; (Oboki et 
al., 2010) obtained by the RIKEN Center for Developmental Biology (Accessory Number: 
CDB0631K; http://www.cdb.riken.jp/arg/mutant%20mice%20list.html) and generated by 
intercrossing Il33-/- mice with the ZP3-Cre germ line deleter strain to remove the neomycin cassette 
as previously described (Kallert et al., 2017). Ucp1-/- mice (B6.129-Ucp1tm1Kz/J) were purchased 
from the Jackson Laboratory. Unless otherwise indicated, all mice were fed a chow diet (3436, 
Provimi Kliba) and sacrificed at 10-16 weeks of age. For diet-induced obesity experiments, 4-
week-old C57BL/6 mice were fed a high fat diet (D12331, Research Diets; containing 58, 26 and 
16% calories from fat, carbohydrate and protein, respectively) for 3 to 7 months. Mice that did not 
gain weight under high fat diet were excluded before experimentation. For vitamin A deprivation 
experiments, 6-week-old C57BL/6 mice were fed a vitamin A deficient diet or the corresponding 
vitamin A sufficient control diet for 10 weeks (E15311 and E15000; Ssniff special diets GmbH). All 
animal experiments were conducted according to the Swiss Veterinary Law and Institutional 
Guidelines and were approved by the Swiss Authorities. All animals were housed under specific 
pathogen-free conditions, in a 22°C temperature-controlled room with a 12h light – 12h dark cycle 
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and had free access to food and water. All metabolic experiments (glucose and insulin tolerance 
tests, GSIS and clamps) were performed with littermate mice.   
 
Human pancreatic islets 
Human islets were isolated from pancreata of cadaver organ donors at the islet transplantation 
center of Lille (France) in accordance with the local Institutional Ethical Committee and were 
provided by the research distribution program through the European Consortium for Islet 
Transplantation, under the supervision of the Juvenile Diabetes Research Foundation (31-2012-
783). Islets were cultured in CMRL-1066 medium (GIBCO) containing 5 mmol/l streptomycin, 2 
mM glutamax and 10% FCS (Invitrogen) in humid environment containing 5% CO2. In this study, 
islets were isolated from five different donors (2 women / 3 men) of 54.4 ± 2.4 years old with a 
body mass index of 29.2 ± 3.8 kg/m2. 
 
METHOD DETAILS  
Mouse pancreatic islets 
To isolate mouse islets, pancreata were perfused through the common bile duct with a HBSS 
collagenase solution (1.4 g/L; collagenase type 4 Worthington) and digested in the same solution 
in a 37°C water bath for 26-28 min. After shaking for 15 seconds, pancreata were washed three 
times with HBSS supplemented with 0.5% bovine serum albumin (BSA) and filtrated through 500 
µm and 70 µm cell strainers (Corning). Islets were retained on the 70 µm cell strainer while the 
cell mixture passing through the 70 µm cell strainer represented the exocrine stoma. Islets were 
double handpicked into a Petri dish with RPMI-1640 (GIBCO) containing 11.1 mM glucose, 100 
units/ml penicillin, 100 µg/ml streptomycin, 2 mM Glutamax, 50 µg/ml gentamycin, 10 µg/ml 
Fungison and 10 % FCS (Invitrogen). Islets were used directly for FACS analysis, RNA isolation 
or cell culture in humid environment containing 5 % CO2.  
 
In vitro islet treatment  
For Il33 gene expression analyses, 80 handpicked mouse or 2 μL of human islet preparation were 
cultured on extracellular matrix-coated 24-well plates and treated overnight with recombinant 
mouse or human IL-1 (10 ng/mL; R&D systems), 33.3 mM of glucose, low endotoxin BSA (Sigma-
Aldrich) and/or BSA-coated sodium palmitate (0.5mM; Sigma-Aldrich) before lysis for RNA 
isolation. For IL-33 protein measurement, 200 handpicked mouse islets or 4 μL of human islet 
preparation were cultured in suspension in a 96-well plate with similar treatments. After 24h 
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culture, islet-free supernatants were stored at -80°C until analysis. For extraction of the whole-
protein fraction of islets, samples were homogenized in lysis buffer (20mM Tris pH 7.5; 150mM 
NaCl; 10% glycerol; 1% Triton X-100; 1% Na3VO4; 1% NaF; 0.5% PMSF and 1 mM EDTA) 
supplemented with a protease inhibitor cocktail (Roche). When indicated, mouse cultured islets 
were treated with 1 μM of all-trans retinoic acid (R2625; Sigma-Aldrich) for 24h, 2 μM of the 
synthetic RAR receptor antagonist LE135 (SML0809; Sigma-Aldrich) for 24h or the neutralizing 
anti-mouse IL-13 (0.05 μg/mL) and anti-mouse GM-CSF (1.25 μg/mL) Functional Grade Purified 
antibodies and corresponding isotypes for 48h (Thermo Fisher Scientific). BALB/c islets were 
stimulated ex vivo with IL-2 and IL-33 (10 ng/mg; Thermo Fisher Scientific) for 72h.  
 
In vitro glucose- and potassium chloride-stimulated insulin secretion assays  
For ex vivo insulin secretion stimulation assays, mouse islets were cultured for 24h and then pre-
incubated for 30 min in modified Krebs-Ringer bicarbonate buffer (KRB; 115 mM NaCl, 4.7 mM 
KCl, 2.6 mM CaCl2 2H2O, 1.2 mM KH2PO4, 1.2 mM MgSO4 2H2O, 10 mM HEPES, 0.5 % bovine 
serum albumin, pH 7.4) containing 2.8 mM glucose. KRB was then replaced by KRB with 2.8 mM 
glucose and collected after 1h to determine the basal insulin release. This was followed by 1h 
incubation in KRB with 16.7 mM glucose (GSIS) or with KRB with 2.8 mM glucose supplemented 
with 25 mM of potassium chloride to determine the glucose- or potassium chloride-stimulated 
insulin release. After supernatant collection, islet protein content was extracted with 0.18 N 
hydrochloride acid in 70% ethanol to measure insulin content (20 islets in 500 μL). For GSIS 
following an in vitro treatment, islets were resting for 48h and then treated for 24h with all-trans 
retinoic acid or 48h with ILC2-conditioned or control media before GSIS. 
 
In vivo Glucose and Insulin Tolerance Tests  
For glucose tolerance tests (GTT), mice were fasted for 6h in the morning and then injected with 
glucose (2 g per kg of body weight) intraperitoneally (i.p.). For insulin tolerance tests, mice were 
fasted for 3h in the morning and i.p. injected with human insulin (Novorapid, Novo Nordisk) (1U 
per kg of body weight) diluted in saline solution. Blood glucose was sampled from the mouse tail 
vein every 15–30 min following glucose or insulin injection and measured using a glucometer 
(Freestyle, Abbott Diabetes Care Inc.).  
 
 
 
Glucose clamp studies 
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Glucose clamp studies were performed in freely moving mice as previously described (Wueest et 
al., 2014). Steady state glucose infusion rate was calculated once glucose infusion reached a 
constant rate with blood glucose levels at 5 mmol/l (80-90 min after the start of insulin infusion). 
Thereafter, blood glucose concentration was kept constant at 5 mmol/l for 15-20 min and glucose 
infusion rate was calculated. Glucose infusion rate and hepatic glucose production were calculated 
as previously described (Wueest et al., 2014). In order to assess tissue specific glucose uptake, 
a bolus (10 μCi) of 2-[1-14C] deoxyglucose was administered via catheter at the end of the steady 
state period. Blood was sampled 2, 15, 25 and 35 min after bolus delivery. Area under the curve 
of disappearing plasma 2-[1-14C] deoxyglucose was used together with tissue-concentration of 
phosphorylated 2-[1-14C] deoxyglucose to calculate glucose uptake. 
 
 
In vivo IL-33 and anti-CD90.2 antibody treatments 
Carrier-free recombinant murine IL-33 (Biolegend) was administered in 100 μL sterile saline by 
i.p. injection for one or three doses every other day at 500 ng per dose in chow diet mice. Mice 
fed a high fat diet received either saline or IL-33 for three doses every other day at 20 μg per kg 
of body weight. Metabolic tests were performed the day after the last injection. Mice were 
sacrificed one or two days after the last injection. For streptozotocin-induced diabetic C57BL/6 
mice, only hyperglycemic mice (i.e. fasting blood glucose > 11 mM) were injected with IL-33 
(starting from day 6 after streptozotocin injection). Anti-CD90.2 (30-H12; 250 μg) antibody or 
corresponding IgG2b (RTK4530) (Biolegend) was administered in 125 μL sterile Phosphate Buffer 
Solution by i.p. injection twice every other day into BALB/c Rag2-/- mice or streptozotocin-induced 
diabetic C57BL/6 Rag2-/- mice (starting from day 6 after streptozotocin injection). 
 
Flow cytometry 
Handpicked islets were isolated and pooled together from at least 3 mice per condition. To obtain 
single cells, islets were gently dispersed with a 0.0125% trypsin-EDTA (GIBCO) solution for 2 min 
in a 37°C water bath, washed with cold FACS buffer (PBS with 0.5% BSA and 5 mM EDTA), 
centrifuged at 300 x g, 4°C for 5 min and resuspended in FACS buffer. After 15 min incubation 
with an Fc blocker (93; Thermo Fisher Scientific), single islet cells were stained with the 
appropriate antibodies or isotypes for 30 min at 4°C in the dark. The following antibodies were 
used: anti-CD45 (30-F11), anti-F4/80 (BM8), anti-CD11c (N418), anti-I-A/I-E (MHC-II) 
(M5/114.15.2), anti-CD3 (145-2C11), anti-B220 (RA3-6B2), anti-NKp46 (29A1.4), anti-Ly6G (1A8 
– Ly6g), anti-CD90.2 (53-2.1), anti-KLRG1 (2F1), anti-CD103 (2E7) and anti-Sca-1 (D7) (from 
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Thermo Fisher Scientific or Biolegend); anti-SIGLEC-F (E50-2440) (from BD bioscience) and anti-
T1/ST2 (DJ8) (from mdbioproducts). ILC2 and ILC3 were identified based on the absence of PE-
labeled lineage markers: anti-F4/80 (BM8), anti-CD11b (M1/70), anti-CD11c (N418), anti-Ly6G 
(RB6-8C5), anti-CD3 (145-2C11), anti-CD4 (GK1.5), anti-CD8a (53-6.7), anti-TCR beta (H57-
597), anti-gamma delta TCR (eBioGL3), anti-CD19 (eBio1D3), anti-CD45R (RA3-6B2), anti-
NKp46 (29A1.4), anti-NK1.1 (PK136) for C57BL/6 mice, anti-CD49b (DX5) for BALB/c mice and 
anti-Ter119 (Ter119) (all from Thermo Fisher Scientific). Anti-NKp46 was excluded from the 
lineage cocktail for the comparative study of ILC2/ILC3. DAPI+ cells and doublet were excluded 
from all analyses. For the detection of transcription factors, cells were fixed and stained using the 
Foxp3-staining kit (Thermo Fisher Scientific) according to the manufacturer’s instructions and 
using anti-GATA3 (TWAJ) and anti-RORγ(t) (B2D) antibodies and a fixable viability dye (all from 
Thermo Fisher Scientific). For quantification of  and α cells in islets, cells were fixed and stained 
with anti-insulin (C27C9; Cell Signaling) and biotinylated anti-glucagon antibodies (Abcam). 
Multiparameter analyses were performed on a LSR-Fortessa flow cytometer (BD Bioscience) and 
analyzed with FlowJo software (Tree Star). For islet cell fraction sorting, anti-CD45 (30-F11) and 
anti-Sca-1 (D7) antibodies were used (from Thermo Fisher Scientific) and sorted with a FACS 
ARIA III cell sorter (BD Biosciences) using FACS Diva software (BD Biosciences).  
 
Aldehyde dehydrogenase activity  
Aldehyde dehydrogenase (ALDH) activity was determined using the ALDEFLUOR staining kit 
(StemCell Technologies) according to the manufacturer’s instructions. Briefly, dispersed islet cells 
were divided into two tubes: one test and one control. In the control tube, ALDH inhibitor 
diethylaminobenzaldehyde (DEAB) was added and incubated for 15 min at 37°C. Then, 
fluorescent ALDH reagent was added in both tubes for 35 min at 37°C. Cells were washed twice 
and incubated with appropriate antibodies for FACS analysis.  
 
Sort-purification of pancreatic ILC2 
Whole pancreata of C57BL/6 mice were collected and pancreatic lymph nodes were removed 
under a stereomicroscope. Pancreata were cut into small pieces with razor blades and washed in 
fresh ice cold PBS. Pancreas pieces were incubated in 1.5 mL DMEM (GIBCO) containing 1 mg/ml 
Collagenase D (Roche) and 0.025 mg/mL DNAse I (Roche) at 37ºC for 15 min. After incubation, 
pancreas pieces were washed with DMEM and supernatant was collected and passed through a 
70 µm cell strainer (Corning). These steps were repeated 3 to 4 times. Isolated cells were washed 
with PBS and purified using a Percoll (GE Healthcare) gradient (40%/80%) at 20°C and 630 x g 
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for 30 min. Cells of the interphase were collected and washed with PBS containing 3% FCS (Gibco 
Life Technologies). Pancreatic ILC2 identified as Lin-CD90.2+Sca-1+CD25+ cells were sorted with 
a FACS Aria (BD Biosciences) and re-analysis showed that cell purity was > 95%.  
 
In vitro stimulation of pancreatic ILC2 
For ILC2-conditioned media, approximately 2000 ILC2 were stimulated for 72h in RPMI containing 
10% FBS with recombinant mouse IL-33 (10 ng/mL; Biolegend) and IL-2 (10 ng/mL; Thermo 
Fisher Scientific) in 96-well round bottom plates (Falcon) at 37°C and 10% CO2. Supernatant was 
recovered and stored at -80°C for further experiments. For control medium, cell-free RPMI 
containing 10% FBS supplemented with the cytokines was incubated for 72h in the same 
conditions.  
 
ILC2 transfer 
Pancreatic ILC2 were purified from C57BL/6 mice that received i.p. three doses of IL-33 (500ng) 
every other day. 3 x 105 cells or PBS were immediately transferred to recipient Rag2-/-γc-/- mice by 
a single intravenous injection. 2h later and the next 2 days, recipient mice were treated with three 
doses of IL-33 (500ng) before performing GTT and islet isolation for ex vivo GSIS assays.  
 
Histological analyses  
For -Galactosidase detection, pancreata from Il33Gt/+ and Il33+/+ littermates were embedded in 
OCT Tissue Tek and frozen in liquid nitrogen. Pancreas sections were fixed and stained with 
chromogenic substrate X-Gal overnight using a LacZ Tissue staining kit (InvivoGen) according to 
the manufacturer’s instructions. Sections were counterstained by nuclear Fast Red (Sigma), 
mounted with Mounting medium (Dako) and analyzed with a widefield microscope (Olympus BX63 
Apollo). For  cell area analysis, pancreata of saline- and IL-33-treated mice were fixed overnight 
in 4% paraformaldehyde at 4°C, followed by paraffin embedding. Sections were deparaffinized, 
re-hydrated and incubated overnight at 4°C with Guinea pig anti-insulin (Dako; A0564), followed 
by detection with Alexa657-conjugated Goat anti–guinea pig IgG (Thermo Fischer Scientific), 
counterstained with DAPI and mounted with Mounting medium (Dako). Pancreas sections were 
analyzed using a Hamamatsu flash 4.0 camera with a 4x Nikon Objective NA 0.2 and automatically 
scanned using a Nikon NiE with Prior PL-200 slide loading robot. Insulin+ area and distribution 
were calculated with NIS-Elements software (Nikon). For immunofluorescence staining of ILC2, 
pancreata of C57BL/6 Rag2-/- mice were embedded in OCT Tissue Tek and frozen in liquid 
nitrogen. Sections were fixed for 5 min in acetone at room temperature. They were then blocked 
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with PBS containing 1% BSA (Sigma-Aldrich) for 30 min at room temperature and stained with 
Alexa657-conjugated anti-CD45.2 (104) and PE-conjugated anti-KLRG1 (2F1-KLRG1) from 
Biolegend and anti-NKp46 (R&D systems, AF2225) overnight at 4°C, followed by detection with 
Alexa488-conjugated Donkey anti-goat IgG (Thermo Fisher scientific) for 1h at room temperature 
and counterstained with DAPI. The slices were mounted (Fluoromount-G, Thermo Fisher 
Scientific) and analyzed with a widefield microscope (Leica DMI 4000). 
 
Immunocytochemistry of islet cells 
For staining of mouse islet cells, islet Sca-1+ cells and Sca-1- cells were sort-purified; Sca-1- cells 
were further separated between cells with a high FSC/SSC profile that are enriched in  cells and 
the rest. Following cytospin (Hettich) onto glass PolysineTM slides, cells were fixed with 4% 
paraformaldehyde (Sigma Aldrich) for 10 min, permeabilized with 0.1% Triton-X-100 for 5 min, 
blocked with PBS supplemented with 0.1% Tween 20, 1% BSA (Sigma Aldrich) and 0.3 M glycine 
for 30 min at room temperature. Cells were stained with Rabbit anti-Vimentin (Abcam; EPR3776) 
overnight at 4°C, followed by detection with Alexa488-conjugated Donkey anti-rabbit IgG 
(Biolegend) and counterstaining with DAPI, mounted with Mounting medium (Dako) and analyzed 
with a widefield microscope (Olympus BX63 Apollo).  
 
Bone marrow-derived dendritic cells 
4 x 106 bone marrow cells per well were cultured in a 6 well plate (Nunc) in supplemented IMDM 
(Sigma Aldrich) in the presence of 200 ng/ml FMS-like tyrosine kinase ligand (FLT3l, A. Rolink, 
University of Basel, Switzerland) at 37ºC and 10% CO2 as previously described (Brasel et al., 
2000). After 6-7 days, BM-DCs were harvested, washed with PBS and used for overnight 
stimulation with IL-13 and Csf2 (10 ng/mL; Thermo Fisher Scientific) or IL-33 (10 ng/mL ; 
Biolegend). Cells were harvested afterwards and used for RNA isolation. 
 
Streptozotocin-induced β cell death  
Streptozotocin (Sigma-Aldrich) was dissolved in citrate buffer (pH 4.5) and was injected once i.p. 
into 6 hour-fasted C57BL/6 mice (150 mg per kg of body weight) or C57BL/6 Rag2-/- mice (120 
mg per kg of body weight).  
In situ pancreatic perfusion  
In situ pancreatic perfusion was performed in anesthetized mice treated with saline or IL-33 (three 
doses) as previously described(Maechler et al., 2002) with a perfusion rate of 1.5 ml/min 
(Maechler et al., 2002).  
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Protein measurement assays 
Insulin concentrations were determined using a mouse/rat insulin kit (Mesoscale Discovery) 
according to the manufacturer’s instructions. Mouse Csf2, IL-5 and human IL-33 concentrations 
were measured using the mouse GM-CSF Tissue Culture Kit, the V-plex mouse IL-5 and the U-
plex human IL-33 (Mesoscale Discovery) according to the manufacturer’s instructions. Mouse IL-
33 was measured using the U-plex mouse IL-33 (Mesoscale Discovery); protocol was improved 
to achieve a lower limit of detection (LLOD) of 0.31 ± 0.07 pg/mL (Mean ± SD; n = 4). Mouse IL-
13 was measured using mouse IL-13 Platinum ELISA (Thermo Fisher Scientific) according to the 
manufacturer’s instructions.  
 
RNA extraction and qRT-PCR 
Total RNA was extracted using the Nucleo Spin RNA II Kit (Machery Nagel) or RNeasy Mini Kit 
(QIAGEN) for islets and bone marrow-derived dendritic cells, RNeasy Lipid Tissue (QIAGEN) for 
epididymal adipose tissue and PureLink RNA Micro Scale Kit (Invitogren) for FACS-sorted cells. 
cDNA was prepared with random hexamers (Microsynth) and Superscript II (Invitrogen) according 
to manufacturer’s instructions. Gene expression was determined with TaqMan assays and the 
real time PCR system 7500 (Applied Biosystems). Data were normalized with the geometrical 
mean of 18S and  actin mRNA (18S was used for human samples) and quantified using the 
comparative 2-ΔΔCT method. The following TaqMan assays (ThermoFisher scientific) were used: 
18s: Mm99999901; Actb: Mm00607939; Acta2: Mm00725412; Aldh1a2: Mm00501306; Areg: 
Mm00437583; Ccl2: Mm00441242; Csf2: Mm01290062; Cxcl1: Mm00433859; Emr1: 
Mm00802529; Flt3: Mm00439016; Gcg: Mm00801714; Ifng: Mm01168133; Il10: Mm01288386; 
Il13: Mm00434204; Il1b: Mm00434228; Il1rl1: Mm00516117; Il4: Mm00445258; Il5: Mm00439646; 
Il22: Mm01226722; Il25: Mm00499822; IL33: Hs01125943; Il33: Mm00505403; Ins2: 
Mm00731595; Rara: Mm01296312; Rarb: Mm01319677; Rarg: Mm00441091; Rxra: 
Mm00441185; Tgfb: Mm01178820; Tslp: Mm01157588; Vim: Mm01333430. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS  
Data were routinely presented as mean ± standard error of mean (SEM). Significance was 
assessed by the methods specified in each individual figure legend using GraphPad Prism 7 
(GraphPad Software). “n” numbers indicate biological replicates for in vitro experiments or number 
of mice for in vivo studies. Outliers were identified according to the two standard deviation method.  
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